Skip to contentHome page Seeking Alpha - Power to InvestorsTranscriptsSep. 28, 2025 9:30 PM ETUnited Therapeutics Corporation (UTHR) StockUTHRSA Transcripts155.62K FollowersUnited Therapeutics Corporation (NASDAQ:UTHR) Phase 3 TETON-2 Results Conference Call TranscriptCompany ParticipantsHarrison Silvers - Manager of Investor RelationsLeigh Peterson - Executive Vice President of Product Development & XenotransplantationMartine Rothblatt - Founder, Chairman & CEOConference Call ParticipantsSteven D. NathanOlivia Brayer - Cantor Fitzgerald & Co., Research DivisionAndreas Argyrides - Oppenheimer & Co. Inc., Research DivisionJoseph Thome - TD Cowen, Research DivisionLisa Walter - RBC Capital Markets, Research DivisionJessica Fye - JPMorgan Chase & Co, Research DivisionJason Gerberry - BofA Securities, Research DivisionPresentationOperatorGood afternoon, and welcome to the United Therapeutics Corporation Phase 3 TETON-2 Results Conference Call. My name is Drew, and I will be your conference operator today. [Operator Instructions] Please note that this call is being recorded. I would now like to turn the webcast over to Harry Silvers, Investor Relations Manager at United Therapeutics.Harrison SilversManager of Investor RelationsThank you, Drew. Good day, everyone. It is my pleasure to welcome you to the United Therapeutics Corporation Phase 3 TETON-2 results conference call.Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties. We assume no obligation to update forward-looking statements.Today's remarks may discuss the progress and results of clinical trials or other developments with respect to our products. These remarks are intended solely to educate investors and are not intended to serve as the basis for medical decision-making or to suggest that any products are safe and effective for any unapproved or investigational uses. Full prescribing information for the products is available on our website.Accompanying me on today's call are Dr. SteveRead more current UTHR analysis and newsView all earnings call transcriptsCommentsRecommended For YouAbout UTHR StockSymbolLast Price% Chg1D5D1M6M1Y5Y10YMarket CapRev Growth (YoY)Short InterestPrev. CloseMore on UTHRTrending AnalysisTrending NewsSeeking Alpha - Power to InvestorsPower to InvestorsFollow usDownload appContact usSubscription Support: 1-347-509-6837© 2025 Seeking AlphaTo ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.